Cibinqo, abrocitinib
Named-patient access overview. Cibinqo is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Cibinqo
Cibinqo (abrocitinib) is manufactured by Pfizer and indicated for Moderate-to-severe atopic dermatitis in adults. It is an oral small molecule (JAK1 inhibitor) approved by the US FDA in 2022 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Cibinqo
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Cibinqo for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Cibinqo is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Country coverage
Reserve Meds publishes detailed country deep-dives for our most-requested medications. Cibinqo country deep-dives are not yet published; we are expanding coverage as the cohort grows. If you are pursuing Cibinqo for a patient in the UAE, Saudi Arabia, India, Egypt, Pakistan, or another market we serve, submit a request and our clinical team will match the destination to the appropriate regulatory pathway and timeline.
Reserved for you. Cibinqo is in coordination scope for the first cohort. Country-specific pricing and timing are confirmed once a coordinator reviews your case.
Start a request for Cibinqo
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.